Patent Issued for Antibody molecules for cancer treatment (USPTO 11795219).
In: Immunotherapy Weekly, 2023-11-16, S. 1884-1884
serialPeriodical
Zugriff:
Boehringer Ingelheim International GmbH has been granted a patent for antibody molecules that have potential applications in cancer treatment. The patent describes the development of anti-PD1 and anti-LAG3 antibodies that have shown improved therapeutic properties compared to existing molecules. These antibodies have demonstrated enhanced activation of T cells and longer half-life, making them more effective in treating cancers. The patent also includes information on the amino acid sequences of the antibody molecules and their potential use in pharmaceutical compositions for the treatment of solid and soft-tissue tumors, including lung cancer. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Antibody molecules for cancer treatment (USPTO 11795219).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-11-16, S. 1884-1884 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|